5-hydroxypentyl carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-hydroxypentyl carbamate
• 化学式: C₆H₁₃NO₃
• 分子量: 147.174
• InChiKey: REGOQXFAFQTHLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,5-戊二醇 、 尿素 在 indium(III) triflate 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.5h， 以65%的产率得到5-hydroxypentyl carbamate
  参考文献：
  名称：

  铟 (III)-催化合成伯氨基甲酸酯和 N-取代脲

  摘要：

  已经开发出一种三氟甲磺酸铟催化的醇和尿素合成伯氨基甲酸酯，作为一种环保的羰基来源。各种直链、支链和环状醇以良好到极好的收率转化为相应的氨基甲酸酯。该方法还通过胺的氨基甲酰化提供了获得 N-取代脲的途径。所有产品均通过简单过滤或结晶得到，无需色谱纯化。机理研究表明，氨基甲酰化反应是通过与铟的 O 配位活化尿素进行的，然后是醇或胺对尿素羰基中心的亲核攻击。原料和催化剂廉价易得，反应时间短，

  DOI：

  10.1055/s-0040-1720927

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018205948A1

  公开（公告）日：2018-11-15

  Provided are benzoxazolinone sulfonamide derivatives that inhibit Na v1.7 activity, pharmaceutical compositions containing them and their use in therapy for the treatment of diseases mediated by Na v1.7 activity.

  提供了抑制Na v1.7活性的苯并噁唑啉磺酰胺衍生物，含有它们的药物组合物以及它们在治疗由Na v1.7活性介导的疾病中的用途。
• QUINOLYL-CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF
  申请人：Primegene (Beijing) Co., Ltd.

  公开号：EP3950677A1

  公开（公告）日：2022-02-09

  Provided is a quinolyl-containing compound as shown in general formula (I) or (II) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotopic label, or an isomer thereof, and further provided are a pharmaceutical composition comprising the compound and use of the compound and the pharmaceutical composition. The provided compound has a dual molecule function, can serve as multi -target inhibitors of novel tyrosine kinase/histone deacetylase, can simultaneously achieve the effect of two inhibitors, has excellent biological activity and pharmacokinetic properties, and has the application potential particularly in the field of treatment of tumors.

  提供的是通式(I)或(II)所示的含有喹诺啉基团的化合物，或其药用可接受盐、溶剂合物、活性代谢物、多形体、同位素标记或异构体，进一步提供了包含该化合物的药物组合物以及该化合物和药物组合物的用途。所提供的化合物具有双分子功能，可作为新型酪氨酸激酶/组蛋白去乙酰化酶的多靶点抑制剂，可以同时实现两种抑制剂的效果，具有优异的生物活性和药代动力学特性，并具有在肿瘤治疗领域特别的应用潜力。
• Novel substituted N-(3-hydroxy-4-piperidinyl)benzamides
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0299566A2

  公开（公告）日：1989-01-18

  Novel N-(3-hydroxy-4-piperidinyl)substituted benzamides of formula wherein: R¹ is hydrogen, C₁₋₆alkyl, arylC₁₋₆alkyl, C₁₋₆alkylcarbonyl, aminoC₁₋₆alkyl or mono- and di(C₁₋₆alkyl)aminoC₁₋₆alkyl; R² is hydrogen or C₁₋₆alkyl; R³, R⁴ and R⁵ each independently are hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy, halo, hydroxy, cyano, nitro, amino, mono- and di(C₁₋₆alkyl)­amino, aminocarbonyl, arylcarbonylamino, C₁₋₆alkylcarbonylamino, C₁₋₆alkylcarbonyl, C₁₋₆alkylcarbonyloxy, aminosulfonyl, C₁₋₆alkylamino­sulfonyl, C₁₋₆alkylsulfinyl, C₁₋₆alkylsulfonyl, C₁₋₆alkylthio, mercapto, trifluoromethyl, arylC₁₋₆alkyloxy or aryloxy; Alk is a C₁₋₆alkanediy; X is O, S, NR⁶ C(=O) or C(=S); Het is a five- or six membered heterocyclic ring being optionally fused with a six membered carbocyclic ring, and being optionally substituted; the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof, which compounds are gastrointestinal motility stimulating agents; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

  式中的新型 N-(3-羟基-4-哌啶基)取代苯甲酰胺 其中 R¹ 是氢、C₁₋₆烷基、芳基C₁₋₆烷基、C₁₋₆烷基羰基、氨基C₁₋₆烷基或单-和二(C₁₋₆烷基)氨基C₁₋₆烷基； R² 是氢或 C₁₋₆ 烷基； R³、R⁴ 和 R⁵ 各自独立地为氢、C₁₋₆烷基、C₁₋₆烷氧基、卤代、羟基、氰基、硝基、氨基、一(C₁₋₆烷基)氨基和二(C₁₋₆烷基)氨基、氨基羰基、芳基羰基氨基、C₁₋₆烷基羰基氨基、C₁₋₆烷基羰基、C₁₋₆烷基羰基氧基、氨基磺酰基、C₁₋₆烷基氨基磺酰基、C₁₋₆烷基磺酰基、C₁₋₆烷硫基、巯基、三氟甲基、芳基₁₋₆烷氧基或芳基氧基； Alk 是 C₁₋₆ 烷基； X 是 O、S、NR⁶ C(=O) 或 C(=S)； Het 是五或六位杂环，可选择与六位碳环融合，并可选择被取代； 药学上可接受的酸加成盐及其可能的立体化学异构形式，这些化合物是胃肠道蠕动刺激剂；含有这些化合物作为活性成分的药物组合物以及制备所述化合物和药物组合物的方法。
• Polysaccharide and methods
  申请人：THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS

  公开号：US11033632B2

  公开（公告）日：2021-06-15

  There is provided a molecule comprising a chain of seven or more contiguous units of 4,6-dideoxy-4-acylamido-α-pyranose, each pair of units joined by a C1-C2 or a C1-C3 link, the chain having a terminal end and a reducing end, wherein the pyranose ring in the unit of the chain most distal from the reducing end is linked to a cap structure. The cap structure is not a 4,6-dideoxy-4-acylamido-α-pyranose. There are also provided vaccine compositions comprising the molecule and methods of vaccinating an animal NI against infection by a Brucella organism, including methods of distinguishing between a vaccinated and an infected animal. There are further provided novel methods of detecting the presence in a sample of an anti-Brucella antibody.

  本发明提供了一种分子，该分子包括由七个或七个以上连续的 4,6-二脱氧-4-酰氨基-α-吡喃糖单元组成的链，每对单元通过一个 C1-C2 或一个 C1-C3 链节连接，该链具有一个末端和一个还原端，其中离还原端最远的链单元中的吡喃糖环与一个帽结构相连。帽结构不是 4,6-二脱氧-4-酰氨基-α-吡喃糖。还提供了包含该分子的疫苗组合物和接种动物 NI 以防止布鲁氏菌感染的方法，包括区分接种疫苗的动物和受感染的动物的方法。还提供了检测样品中是否存在抗布鲁氏菌抗体的新方法。
• [EN] METHOD OF MAKING CARBAMATE FUNCTIONAL MATERIALS<br/>[FR] PROCÉDÉ DE FABRICATION DE MATIÈRES À FONCTIONNALITÉ CARBAMATE
  申请人：BASF CORP

  公开号：WO2009035667A1

  公开（公告）日：2009-03-19

  A method of making a carbmate functional material comprises reacting a material having an ester group, such as a polymeric, oligomeric, or fatty acid material, with a hydroxy compound having a carbamate group. The reaction is catalyzed by a biocatalyst to form the carbamate-functional material. The carbamate-functional material is combined with a crosslinker having carbamate-reactive groups to make a coating composition.

  一种制备脲基功能材料的方法包括将具有酯基的材料（如聚合物、寡聚物或脂肪酸材料）与具有脲基的羟基化合物反应。该反应在生物催化剂的作用下进行，从而形成脲基功能材料。然后将脲基功能材料与具有脲基反应性基团的交联剂结合，制备成涂层组合物。